siRNA-based SARS-CoV-2 therapies (Aligos Therapeutics/University of Texas)

N/A

Report date: 2025/06/11 11:23:40
NME

Base Information

Drug NamesiRNA-based SARS-CoV-2 therapies (Aligos Therapeutics/University of Texas)
Drug Alias NameALG-152302ALG-152303
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Texas Medical Branch
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of Texas Medical BranchAligos Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A